Recent Updates
Recently added Catalysts

mRNA-1975

Phase 1

Lyme Disease | Monoclonal antibody | Infectious Disease |Moderna, Inc.|Last Updated: Jul 30, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment807

FDA Designations

No designations recorded

Clinical trial landscape

mRNA-1975 · 1 trial · 1 indication

Phase 1 1
NCT05975099A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of AgeLyme Disease
COMPLETED807 Analytics
PHASE1COMPLETED
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
Lyme DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Up to 7 days after Day 1 injection

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection
Up to 7 days after Day 57 injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection
Up to 7 days after Day 169 injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Number of Participants With Unsolicited AEs
Up to 28 days post any injection

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Study Discontinuation
Day 1 up to Month 18

A MAAE is an AE that led to an unscheduled visit to a healthcare practitioner. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor were required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Secondary Endpoints

Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein (Anti-OspA) Binding Immunoglobulin (IgG) Antibodies for Serotype (SR-1) Antigen Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
Days 1, 29, 85 and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-2 Antigen Measured by ELISA
Days 1, 29, 85, and 197
GMC of Anti-OspA Binding IgG Antibodies for SR-3 Antigen Measured by ELISA
Days 1, 29, 85 and 197
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
mRNA-1975: Dose 1EXPERIMENTALParticipants will receive 3 intramuscular (IM) injections of the mRNA-1975 vaccine at Dose Level 1 on Days 1, 57, and 169.
mRNA-1975: Dose 2EXPERIMENTALParticipants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 2 on Days 1, 57, and 169.
mRNA-1975: Dose 3EXPERIMENTALParticipants will receive 3 IM injections of the mRNA-1975 vaccine at Dose Level 3 on Days 1, 57, and 169.
mRNA-1975: Dose 4EXPERIMENTALParticipants will receive 3 IM injections of the mRNA-1975 vaccine at Dose level 4 on Days 1, 57, and 169.
mRNA-1982: Dose 1EXPERIMENTALParticipants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 1 on Days 1, 57, and 169.
mRNA-1982: Dose 2EXPERIMENTALParticipants will receive 3 IM injections of the mRNA-1982 vaccine at Dose Level 2 on Days 1, 57, and 169.
mRNA-1982: Dose 3EXPERIMENTALParticipants will receive 3 IM injections of the mRNA-1982 vaccine at Dose level 3 on Days 1, 57, and 169.
PlaceboPLACEBO_COMPARATORParticipants will receive 3 IM injections of vaccine-matching placebo on Days 1, 57, and 169.

Interventions

NameTypeDescription
mRNA-1975BIOLOGICALDispersion delivered IM
mRNA-1982BIOLOGICALDispersion delivered IM
PlaceboBIOLOGICALSolution delivered IM
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersYes
Study Sites20

Inclusion Criteria: * Body mass index of 18 to 39 kilograms/square meter (inclusive) at the Screening Visit. * Participants of nonchildbearing potential may be enrolled in the study. * For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstaine...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMAug 30, 2026NCT05975099TRIAL_REMOVED: changed
MEDIUMAug 30, 2026NCT05975099TRIAL_REMOVED: changed
MEDIUMAug 30, 2026NCT05975099TRIAL_REMOVED: changed

Frequently asked questions about mRNA-1975

What is mRNA-1975 used for?

mRNA-1975 is an investigational messenger RNA (mRNA) vaccine being developed for the prevention of Lyme disease. It is designed to elicit an immune response against the bacterium that causes Lyme disease, which is transmitted through tick bites. The vaccine is currently in clinical development and has not been approved by regulatory authorities.

Who makes mRNA-1975?

mRNA-1975 is being developed by Moderna, Inc., a biotechnology company publicly traded under the ticker symbol MRNA on the Nasdaq stock exchange. Moderna is known for its mRNA-based therapeutic and vaccine platform, and mRNA-1975 is one of its candidates targeting infectious diseases.

What phase is mRNA-1975 in?

mRNA-1975 is in Phase 1 clinical development. A Phase 1 study has been completed, evaluating the safety and immunogenicity of the vaccine in healthy adults aged 18 through 70 years. The vaccine is investigational and has not yet received regulatory approval for use outside of clinical trials.

What clinical trials is mRNA-1975 in?

mRNA-1975 has been studied in a Phase 1 clinical trial with the identifier NCT05975099. This randomized, double-blind, placebo-controlled study assessed the safety and immunogenicity of mRNA-1975 and another Moderna Lyme disease vaccine candidate, mRNA-1982, in 807 participants in the United States. The trial has been completed.

Is mRNA-1975 the same as mRNA-1982?

No, mRNA-1975 and mRNA-1982 are distinct vaccine candidates developed by Moderna for Lyme disease. Both were evaluated together in the same Phase 1 clinical trial (NCT05975099), but they are separate investigational products with potentially different antigen designs or formulations. Each is being studied for its individual safety and immunogenicity profile.